Brandon Folkes
Stock Analyst at Rodman & Renshaw
(1.70)
# 2,958
Out of 4,814 analysts
47
Total ratings
23.53%
Success rate
-8.14%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $1.02 | +390.20% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $2.23 | +438.12% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.48 | +158.62% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $6.68 | +34.73% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $0.65 | +1,128.88% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $4.54 | +252.42% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $8.11 | +60.30% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $1.01 | +791.09% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $4.44 | +80.38% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $6.04 | +15.89% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.93 | +262.69% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.09 | +817.43% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $4.78 | +9,418.83% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $29.00 | +103.45% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $100.34 | +79.39% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.52 | +4,097.67% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.35 | +41.73% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $27.01 | +18.47% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $2.19 | +1,004,466.21% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $26.94 | -18.34% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $2.75 | +26,081.82% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $68.00 | -41.18% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.16 | +3,338.86% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $20.60 | +142.72% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.02
Upside: +390.20%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.23
Upside: +438.12%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.48
Upside: +158.62%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $6.68
Upside: +34.73%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.65
Upside: +1,128.88%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $4.54
Upside: +252.42%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $8.11
Upside: +60.30%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $1.01
Upside: +791.09%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $4.44
Upside: +80.38%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $6.04
Upside: +15.89%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $1.93
Upside: +262.69%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $1.09
Upside: +817.43%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $4.78
Upside: +9,418.83%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $29.00
Upside: +103.45%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $100.34
Upside: +79.39%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.52
Upside: +4,097.67%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $6.35
Upside: +41.73%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $27.01
Upside: +18.47%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $2.19
Upside: +1,004,466.21%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $26.94
Upside: -18.34%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $2.75
Upside: +26,081.82%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $68.00
Upside: -41.18%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.16
Upside: +3,338.86%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $20.60
Upside: +142.72%